Neural Stem Cell Research Lab

We are looking for a motivated #bioinformatician (immediate position) to analyze #transcriptomic data on #neurodegenerative diseases to join our lab. All PhD, MSc and BSc with relevant experience are welcome to apply! jobstreet.com.sg/en/job/senior-…

Our lab is at the #ADPD2023!! First physical international conference in 3 years! @adpdnet

Check out our latest study on the effects of itanapraced on #Parkinsons disease! Thanks @mnt for the feature 👍🏼

Upcoming ⁦ @devbio_sg virtual ⁩seminar by Associate Professor Quenten Schwarz on interneuron development, happening on 27 October! ⁦ @phil1pingham @MonteiroLab @onsunlau_nus @NSCRLab @HongyanWang9 @Yusuke_Toyama @ReversadeLab @unisaresearch

Upcoming exciting ⁦@devbio_sg⁩ seminar by Anna Akhmanova on #microtubules! ⁦@phil1pingham⁩ ⁦@MonteiroLab⁩ ⁦@onsunlau_nus⁩ ⁦@NSCRLab⁩ @HongyanWang9⁩ ⁦@Yusuke_Toyama⁩ ⁦@ReversadeLab⁩

SCSS Symposium 2022: Registration is open - mailchi.mp/d04991d7e09c/s…

Thanks for the feature! @Ingentium_PD The APP intracellular domain promotes LRRK2 expression to enable feed-forward neurodegenerative mechanisms in Parkinson's disease. magazine.ingentium.com/2022/08/24/the…

An experimental therapy for Alzheimer’s disease can break a molecular loop and protect neurons in mouse models of Parkinson’s disease, hinting similar approaches could prove beneficial for this incurable neurodegenerative condition. @NSCRLab #Neuroscience fcld.ly/2ro163e

Annovis Bio @AnnovisBio has announced that the 1st patient in the Phase 3 clinical trial evaluating buntanetap (aka ANVS401, Posiphen) in early stage #Parkinsons has been dosed; The trial will enroll a total of 450 participants, treatment for 6 months irpages2.eqs.com/websites/annov…

@HongyanWang9 @scisignal Thanks Hongyan! 😁

@NSCRLab @scisignal Congratulations!🎉🎉🎉👍👍👍

Just today, our paper on a feed-forward loop between the APP intracellular domain (AICD) fragment and the kinase LRRK2 which promotes #Parkinsonsdisease pathology was published on @scisignal #ScienceSignalingResearch science.org/doi/10.1126/sc…

We propose that AICD cooperates with transcription factor of FOXO3a to promote LRRK2 transcriptional activation and expression. Experimental drug, itanapraced, inhibits LRRK2-mediated neurotoxicity. @ScienceMagazine @scisignal #Parkinsonsdisease

@ScienceMagazine @scisignal Thanks for the shout out!

An experimental treatment for Alzheimer’s disease can break a molecular loop and protect neurons in mouse models of #ParkinsonsDisease, suggesting similar approaches could prove beneficial for this incurable neurodegenerative condition. fcld.ly/j7bul55 @SciSignal

A positive feedback loop between AICD and #LRRK2 drives #neurodegeneration and mitochondrial dysfunction in #ParkinsonsDisease but can be targeted with the experimental drug itanapraced, show experiments in mice from the Tan and Zeng labs. @mysgh @NSCRLab fcld.ly/ccrcssg

New paper from the @NSCRLab! They found that in cultured neurons & brain tissue from mouse models of #ParkinsonsDisease, LRRK2-mediated phosphorylation of APP increased the abundance and activity of the APP intracellular domain. 🧠 @scisignal bit.ly/3PGudRC

A self-sustaining molecular loop that drives Parkinson’s disease can be targeted in mice, new research answers a longstanding question about Wnt signaling, and more in this week’s new issue of Science Signaling. fcld.ly/q53lnia

We found that blood miR-150-5p was upregulated in #AlzheimersDisease #Dementia which could be a promising cost-effective and non-invasive biomarker for AD. Read our article published in @journal_ad! pubmed.ncbi.nlm.nih.gov/35811521/

Earlier this year, we published on @BioMedCentral reporting the increased expression of pathological markers in Parkinson’s disease dementia post-mortem brains compared to dementia with Lewy bodies. Check it out! #Parkinsonsdisease #lewybody bmcneurosci.biomedcentral.com/articles/10.11…